Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CDH13 antisense RNA 1 (CDH13-AS1)
- Target
- CDH13-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Non-coding RNA (ncRNA)
01
Overview
CDH13 antisense RNA 1 (CDH13-AS1) is a long non-coding antisense RNA transcribed from the CDH13 locus. It regulates gene expression post-transcriptionally by acting as a competing endogenous RNA (ceRNA) that sponges specific miRNAs, such as miR-324-3p, thereby affecting cell proliferation and apoptosis, particularly in neurodegenerative disease models like Alzheimer's disease. CDH13-AS1 is implicated in an intricate network of non-coding RNAs controlling T-cadherin (CDH13), impacting cardiovascular, metabolic, oncogenic, and neurodegenerative conditions. Its expression and interactions position it as both a promising biomarker and a potential therapeutic target for RNA-based therapies.
- Other names
- CDH13-AS1RP11-543N12.1
02
Mechanism of action
Sponging specific miRNAs (e.g., miR-324-3p) to relieve repression of CDH13 and promote apoptosis; Recruiting epigenetic enzymes (e.g., DNA methyltransferases)
03
Biological functions
Epigenetic regulation of gene expression (through interaction with miRNAs and chromatin modifiers)Post-transcriptional regulation (sponging miRNAs)Regulation of cell proliferation and apoptosis
04
Disease associations
Neurodegenerative disease (notably, biomarker and therapeutic target potential in Alzheimer's disease models)Cancer (epigenetic and expression regulatory roles)Cardiovascular disease (via modulation of CDH13/T-cadherin expression)Metabolic disease (CDH13/T-cadherin axis involvement)
05
Safety considerations
As a non-coding RNA, off-target and delivery challenges are anticipated for any therapy targeting CDH13-AS1 or its network (no clinical safety concerns noted so far)
06
Biomarkers
CDH13-AS1 expression (proposed as biomarker for Alzheimer's disease model, possibly for certain cancers)miR-324-3p expression
Beyond the preview
Go deeper on CDH13 antisense RNA 1 (CDH13-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDH13 antisense RNA 1 (CDH13-AS1).